1. Home
  2. ORC vs OMER Comparison

ORC vs OMER Comparison

Compare ORC & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orchid Island Capital Inc.

ORC

Orchid Island Capital Inc.

HOLD

Current Price

$7.36

Market Cap

1.2B

Sector

Real Estate

ML Signal

HOLD

Logo Omeros Corporation

OMER

Omeros Corporation

HOLD

Current Price

$10.89

Market Cap

628.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ORC
OMER
Founded
2010
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
628.9M
IPO Year
2013
2009

Fundamental Metrics

Financial Performance
Metric
ORC
OMER
Price
$7.36
$10.89
Analyst Decision
Hold
Strong Buy
Analyst Count
2
5
Target Price
N/A
$27.50
AVG Volume (30 Days)
5.4M
1.7M
Earning Date
10-23-2025
11-13-2025
Dividend Yield
19.59%
N/A
EPS Growth
N/A
N/A
EPS
0.57
N/A
Revenue
$80,187,000.00
N/A
Revenue This Year
$82.99
N/A
Revenue Next Year
$61.79
N/A
P/E Ratio
$12.81
N/A
Revenue Growth
5.93
N/A
52 Week Low
$5.69
$2.95
52 Week High
$9.01
$13.60

Technical Indicators

Market Signals
Indicator
ORC
OMER
Relative Strength Index (RSI) 56.06 70.10
Support Level $7.14 $9.31
Resistance Level $7.41 $11.03
Average True Range (ATR) 0.11 0.75
MACD 0.01 0.17
Stochastic Oscillator 84.62 95.17

Price Performance

Historical Comparison
ORC
OMER

About ORC Orchid Island Capital Inc.

Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: